Henke Peter K, Nicklas John M, Obi Andrea
Department of Surgery, University of Michigan Health System, Frankel Cardiovascular Center, Ann Arbor, Michigan, USA.
Department of Medicine, Brown University Medical School, Providence, Rhode Island, USA.
Res Pract Thromb Haemost. 2023 Nov 20;7(8):102268. doi: 10.1016/j.rpth.2023.102268. eCollection 2023 Nov.
Herein, we review the current processes that govern experimental deep vein thrombus (DVT) resolution. How the human DVT resolves at the molecular and cellular level is not well known due to limited specimen availability. Experimentally, the thrombus resolution resembles wound healing, with early neutrophil-mediated actions followed by monocyte/macrophage-mediated events, including neovascularization, fibrinolysis, and eventually collagen replacement. Potential therapeutic targets are described, and coupling with site-directed approaches to mitigate off-target effects is the long-term goal. Similarly, timing of adjunctive agents to accelerate DVT resolution is an area that is only starting to be considered. There is much critical research that is needed in this area.
在此,我们回顾了目前控制实验性深静脉血栓形成(DVT)溶解的过程。由于标本获取有限,人类DVT在分子和细胞水平上如何溶解尚不清楚。在实验中,血栓溶解类似于伤口愈合,早期由中性粒细胞介导,随后是单核细胞/巨噬细胞介导的过程,包括新血管形成、纤维蛋白溶解,最终是胶原蛋白替代。文中描述了潜在的治疗靶点,与定点方法相结合以减轻脱靶效应是长期目标。同样,使用辅助药物加速DVT溶解的时机也是一个才刚刚开始被考虑的领域。该领域还需要大量关键研究。